Search

Axsome Therapeutics Inc

Lezárt

SzektorEgészségügy

144.04 -6.97

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

143.3

Maximum

146.11

Fő mutatók

By Trading Economics

Bevétel

13M

-51M

Értékesítés

27M

218M

Egy részvényre jutó nyereség

-0.99

Profit margin

-23.498

Munkavállalók

1,346

EBITDA

14M

-47M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+97.1% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 2.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-2.7B

8.2B

Előző nyitás

151.01

Előző zárás

144.04

Axsome Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 23. 23:06 UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours, in line with broader market trends despite mixed economic signals and rising oil prices.

2026. okt. 22. 20:13 UTC

Axsome Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a notably weak performance below its 20-day moving average.

2026. okt. 21. 23:11 UTC

Axsome Therapeutics Inc is trading higher in after-market hours, rebounding from a brief dip earlier in the session and reaching its highest point of the day.

2026. okt. 20. 23:51 UTC

Axsome Therapeutics Inc shares advanced sharply in after-market trading, rising from a low shortly after the market closed to a session high.

2026. okt. 19. 23:56 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours, having pulled back from an initial gain shortly after the market closed.

2026. okt. 16. 20:07 UTC

Axsome Therapeutics Inc shares are declining, consistent with broader market weakness, reaching their lowest point since Thursday's close amid a subdued trading environment.

2026. okt. 15. 20:07 UTC

Axsome Therapeutics Inc shares are declining, following volatility earlier in the session, and remain significantly below their 20-day moving average.

2026. okt. 14. 21:01 UTC

Axsome Therapeutics Inc shares are moving lower in after-market trading amid a broader market decline following increased inflation concerns and potential Fed interest rate hikes.

2026. okt. 13. 20:01 UTC

Axsome Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, contrasting with the upward momentum observed since Monday's close.

2026. okt. 12. 23:41 UTC

Axsome Therapeutics Inc shares advanced in after-market trading, showing gains after an initial dip, despite a broader decline over the past month.

2026. okt. 9. 19:35 UTC

Axsome Therapeutics Inc shares fell sharply during the current market session, reflecting a broader trend of lower daily closes over the past month.

2026. okt. 8. 23:01 UTC

Axsome Therapeutics Inc shares are modestly lower in after-market trading, continuing a downward trend since Thursday's close and remaining below its 20-day moving average.

2026. okt. 7. 20:08 UTC

News

Axsome Therapeutics Inc shares fell as the company announced its third-quarter financial results will be released on November 2, 2026, before market open.

2026. okt. 6. 22:35 UTC

Axsome Therapeutics Inc's shares are higher in after-market hours, despite a recent decline and nine consecutive sessions finishing lower.

2026. okt. 5. 19:35 UTC

Axsome Therapeutics Inc shares fell, continuing a downward trend with seven consecutive sessions of lower closes since the market opened.

2026. okt. 2. 20:12 UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, continuing a trend with six consecutive sessions finishing lower.

2026. okt. 1. 20:07 UTC

Axsome Therapeutics Inc shares fell sharply, closing lower than Wednesday and remaining significantly below the 20-day moving average.

2026. szept. 30. 21:01 UTC

Axsome Therapeutics Inc's shares rose in after-market trading, supported by positive economic indicators, including stronger GDP growth and robust personal spending.

2026. szept. 29. 20:01 UTC

News

Shares of Axsome Therapeutics fell as Deutsche Bank maintained its Buy rating but lowered the price target to $267 amid reevaluated market conditions.

2026. szept. 28. 20:07 UTC

News

Axsome Therapeutics Inc shares fell amid a broader market downturn, despite presenting new Alzheimer’s agitation survey data at Psych Congress 2026.

2026. szept. 25. 20:07 UTC

News

Axsome Therapeutics shares fell after Morgan Stanley cut its price target to $247 from $251, contributing to a decline near the lower end of its one-month range.

2026. szept. 24. 20:07 UTC

Axsome Therapeutics Inc's shares advanced, recovering from four consecutive sessions of losses, though they remain below their 20-day moving average.

2026. szept. 23. 23:35 UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours following unusual activity, though it remains significantly below its 20-day moving average.

2026. szept. 22. 19:45 UTC

Axsome Therapeutics Inc shares fell sharply, trading below their 20-day moving average, marking three consecutive sessions of declines amid a weaker market trend.

2026. szept. 21. 20:12 UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, remaining near the lower end of its one-month trading range and below its 20-day moving average.

2026. szept. 18. 19:46 UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

2026. szept. 16. 20:10 UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

2026. szept. 15. 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

2026. szept. 14. 20:07 UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

2026. szept. 12. 00:01 UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

Társak összehasonlítása

Árváltozás

Axsome Therapeutics Inc Előrejelzés

Célár

By TipRanks

97.1% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 285.875 USD  97.1%

Magas 380 USD

Alacsony 247 USD

17 Wall Street elemző 12 hónapos célárain alapulva a(z)Axsome Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

17 ratings

16

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat